San Francisco, California-- (Newsfile Corp. - March 17, 2025) - Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the ...

Novo Nordisk A/S, No. 25-cv-00713, alleges that the company and its key executives committed securities violations during the Phase 3 trial of CagriSema, known as REDEFINE-1. Investors who ...

After 2 positive trials, low-dose colchicine’ got the FDA nod for CV reduction but then the CLEAR SYNERGY trial found no ...

Last month, the U.S. Food and Drug Administration (the “FDA”) announced in a Declaratory Order the resolution of the shortage of semaglutide ...

The Cigna Group Completes Sale of Medicare Businesses to HCSC The transaction is not expected to disrupt coverage or s ...

Novo Nordisk A/S, No. 25-cv-00713, accuses the company and certain top executives of securities violations related to disclosures about the drug's Phase 3 trial, dubbed REDEFINE-1. The plaintiffs ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease. WHY IT'S IMPORTANT ...

The Phase 3b/4 EXSCEL (EXenatide Study of Cardiovascular Event Lowering) showed the drug did not increase cardiovascular (CV) risk ... to diabetes patients. Novo Nordisk's rival GLP-1 treatment ...

Scaling Obesity and CV-Met For the new obesity therapeutics making ... Eli Lilly (valued at over $500 billion by end 2023) and Novo Nordisk (valued at over $450 billion), could achieve this ...